KAM
ALXN

Krensavage Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Krensavage Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-6,912
Closed -$1.06M – 14
2021
Q1 		$1.06M Sell
6,912
-357,362
-98% -$55.3M 0.37% 10
2020
Q4 		$56.9M Sell
364,274
-32,301
-8% -$4.15M 16.62% 1
2020
Q3 		$45.4M Sell
396,575
-96,595
-20% -$10.4M 14.45% 2
2020
Q2 		$55.4M Buy
493,170
+31,032
+7% +$3.29M 15.06% 2
2020
Q1 		$41.5M Buy
462,138
+148,582
+47% +$14.6M 13.35% 3
2019
Q4 		$33.9M Buy
313,556
+58,556
+23% +$6.26M 11.57% 4
2019
Q3 		$25M Buy
+255,000
New +$28.7M 9.59% 6

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Krensavage Asset Management's ALXN Position: Q2 2021 in Review

Krensavage Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q2 2021, closing a stake of 6,912 shares — an estimated $1.06M sold.

Krensavage Asset Management first reported a position in ALXN in Q3 2019 and held it in 7 quarters. The position peaked at $56.9M in Q4 2020. 708 funds tracked by Wall St. Rank hold ALXN as of Q2 2021.

  • Krensavage Asset Management reported no remaining Alexion Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Krensavage Asset Management sold 6,912 Alexion Pharmaceuticals shares in Q2 2021, an estimated $1.06M.
  • Krensavage Asset Management first reported a position in Alexion Pharmaceuticals in Q3 2019 and held it in 7 quarters.
  • Krensavage Asset Management's Alexion Pharmaceuticals position peaked at $56.9M in Q4 2020.
  • 708 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2021.

Based on Krensavage Asset Management's 13F filing for Q2 2021, filed 13 Aug 2021.